vimarsana.com

Page 12 - பல்கலைக்கழகம் ஆஃப் நேபிள்ஸ் ஃபெடரீகொ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rousselot Biomedical, a Darling Ingredients brand, joins European ENLIGHT project to develop a 3D living model of pancreatic tissue

Press release content from PR Newswire. The AP news staff was not involved in its creation. Rousselot Biomedical, a Darling Ingredients brand, joins European ENLIGHT project to develop a 3D living model of pancreatic tissue February 22, 2021 GMT Darling International Inc. (PRNewsfoto/Darling International Inc.) IRVING, Texas, Feb. 22, 2021 /PRNewswire/ Darling Ingredients Inc. (NYSE: DAR) today announced that its Rousselot Biomedical brand is joining the European project ENLIGHT. Researchers from academic centers and leading industries across Europe are joining forces to develop a living model of the pancreas to enable better testing of diabetes medication. This model is manufactured using a new method of bioprinting invented at the UMC Utrecht and EPFL, and specialized stem cells studied by ETH Zurich and the University of Naples. With eight European partners a new bioprinter that, using visible light, prints stem cells three-dimensionally into functional pancreatic tissues. T

Discovering the therapeutic applications of medicinal plants

 E-Mail Both Asia and Africa are home to many plants that can be used for the treatment of many diseases and their medicinal properties are gaining interest in western societies. Medicinal plants from Asia and Africa are used for their healing abilities and also have a symbolic meaning in communities. The importance of traditional autochthonous plant remedies plays a crucial role in the health of millions of people of these two continents. Even today, traditional medicine represents the dominant medical system for millions of people showing a significant impact on health care practices. Therefore, traditional operators still represent a vital part of regional healthcare systems. For this reason, pharmaceutical industries consider traditional medicine as a source for the identification of bioactive compounds that can be used in the preparation of synthetic drugs.

Examining resistance to breast cancer treatments

Date Time Examining resistance to breast cancer treatments The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment. Researchers at the Lester and Sue Smith Breast Center and the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine examined gene expression data from preclinical models of ER+ breast cancer and from patients with early ER+/HER2- breast cancer who were participating in neoadjuvant trials of CDK4/6 inhibitors and found an association between high interferon (IFN) signaling and resistance to the treatment. The findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research, may aid in helping doctors identify whi

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.